Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer

doi:10.4240/wjgs.v16.i5.1395

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (565)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

HTML

352

Figures (1-3)

Tables (1-3)

Sum=481

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=62

May 27, 2024 (publication date) through Jun 29, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastrointest Surg. May 27, 2024; 16(5): 1395-1406
Published online May 27, 2024. doi: 10.4240/wjgs.v16.i5.1395

Full Size Figure Download Figure

Figure 2 Kaplan-Meier curve of progression free survival for colorectal cancer patients in a two-year follow-up. A: Progression free survival (PFS) in colorectal cancer (CRC) patient with amplified-mesenchymal-epithelial transition factor (MET) and non-amplified MET; B: PFS in CRC patient with different c-MET protein levels. MET: Mesenchymal-epithelial transition factor; FISH: Fluorescence in situ hybridization; IHC: Immunohistochemistry.

Citation: Yu QX, Fu PY, Zhang C, Li L, Huang WT. Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer. World J Gastrointest Surg 2024; 16(5): 1395-1406
URL: https://www.wjgnet.com/1948-9366/full/v16/i5/1395.htm
DOI: https://dx.doi.org/10.4240/wjgs.v16.i5.1395